{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T18:27:21Z","timestamp":1758392841928,"version":"3.44.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40744-025-00777-3","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T03:18:39Z","timestamp":1753067919000},"page":"925-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guselkumab Efficacy in Biologic-Na\u00efve Participants with Psoriatic Arthritis and Severe Disease Activity: Post Hoc Analysis of a Phase\u00a03 Study"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher T.","family":"Ritchlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6189-5328","authenticated-orcid":false,"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-1729","authenticated-orcid":false,"given":"Maria Sole","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0041-6984","authenticated-orcid":false,"given":"Evan","family":"Leibowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9847-2996","authenticated-orcid":false,"given":"Mohamed","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Rampakakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-3328","authenticated-orcid":false,"given":"Francois","family":"Nantel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-257X","authenticated-orcid":false,"given":"Frederic","family":"Lavie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2130-1246","authenticated-orcid":false,"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"777_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18:465\u201379.","journal-title":"Nat Rev Rheumatol"},{"key":"777_CR2","doi-asserted-by":"publisher","first-page":"e001223","DOI":"10.1136\/rmdopen-2020-001223","volume":"6","author":"G Haugeberg","year":"2020","unstructured":"Haugeberg G, Michelsen B, Kavanaugh A. Impact of skin, musculoskeletal and psychosocial aspects on quality of life in psoriatic arthritis patients: A cross-sectional study of outpatient clinic patients in the biologic treatment era. RMD Open. 2020;6:e001223.","journal-title":"RMD Open"},{"key":"777_CR3","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.3899\/jrheum.121500","volume":"40","author":"JA Husted","year":"2013","unstructured":"Husted JA, Thavaneswaran A, Chandran V, et al. Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. J Rheumatol. 2013;40:1349\u201356.","journal-title":"J Rheumatol"},{"key":"777_CR4","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1136\/annrheumdis-2017-211433","volume":"76","author":"A Kerschbaumer","year":"2017","unstructured":"Kerschbaumer A, Baker D, Smolen JS, et al. The effects of structural damage on functional disability in psoriatic arthritis. Ann Rheum Dis. 2017;76:2038\u201345.","journal-title":"Ann Rheum Dis"},{"key":"777_CR5","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s10067-019-04734-8","volume":"39","author":"SS Zhao","year":"2020","unstructured":"Zhao SS, Miller N, Harrison N, et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020;39:217\u201325.","journal-title":"Clin Rheumatol"},{"key":"777_CR6","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Kristianslund EK, Sexton J, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76:1906\u201310.","journal-title":"Ann Rheum Dis"},{"key":"777_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40744-024-00667-0","volume":"11","author":"E Lubrano","year":"2024","unstructured":"Lubrano E, Scriffignano S, Perrotta FM. Clinical characteristics of \u201csevere\u201d peripheral psoriatic arthritis: a retrospective analysis of a longitudinal cohort. Rheumatol Ther. 2024;11:663\u201374.","journal-title":"Rheumatol Ther."},{"key":"777_CR8","doi-asserted-by":"publisher","first-page":"891863","DOI":"10.3389\/fmed.2022.891863","volume":"9","author":"R Queiro","year":"2022","unstructured":"Queiro R, Seoane-Mato D, Laiz A, et al. Severe disease in patients with recent-onset psoriatic arthritis. Prediction model based on machine learning. Front Med (Lausanne). 2022;9:891863.","journal-title":"Front Med (Lausanne)"},{"key":"777_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/acr.24242","volume":"72","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken). 2020;72:82\u2013109.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"777_CR10","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/acr.22401","volume":"67","author":"L Eder","year":"2015","unstructured":"Eder L, Thavaneswaran A, Chandran V, et al. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 2015;67:264\u201372.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"777_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40257-015-0169-x","volume":"17","author":"MG Lebwohl","year":"2016","unstructured":"Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Am J Clin Dermatol. 2016;17:87\u201397.","journal-title":"Am J Clin Dermatol."},{"key":"777_CR12","doi-asserted-by":"publisher","first-page":"e0234705","DOI":"10.1371\/journal.pone.0234705","volume":"15","author":"JA Sacrist\u00e1n","year":"2020","unstructured":"Sacrist\u00e1n JA, Dilla T, D\u00edaz-Cerezo S, et al. Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature. PLoS One. 2020;15:e0234705.","journal-title":"PLoS One."},{"key":"777_CR13","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3899\/jrheum.160963","volume":"44","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Karki C, Palmer JB, et al. Clinical and patient-reported outcomes in patients with psoriatic arthritis (PsA) by body surface area affected by psoriasis: results from the Corrona PsA\/Spondyloarthritis Registry. J Rheumatol. 2017;44:1151\u20138.","journal-title":"J Rheumatol."},{"key":"777_CR14","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/acr.23249","volume":"69","author":"PJ Mease","year":"2017","unstructured":"Mease PJ, Karki C, Palmer JB, et al. Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. Arthritis Care Res (Hoboken). 2017;69:1692\u20139.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"777_CR15","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3899\/jrheum.190923","volume":"48","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Liu M, Rebello S, et al. Association of nail psoriasis with disease activity measures and impact in psoriatic arthritis: data from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol. 2021;48:520\u20136.","journal-title":"J Rheumatol."},{"key":"777_CR16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3899\/jrheum.171094","volume":"45","author":"PJ Mease","year":"2018","unstructured":"Mease PJ, Palmer JB, Liu M, et al. Influence of axial involvement on clinical characteristics of psoriatic arthritis: analysis from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. J Rheumatol. 2018;45:1389\u201396.","journal-title":"J Rheumatol."},{"key":"777_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40744-020-00221-8","volume":"7","author":"W Tillett","year":"2020","unstructured":"Tillett W, Merola JF, Thaci D, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7:617\u201337.","journal-title":"Rheumatol Ther."},{"key":"777_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/art.41553","volume":"73","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 2021;73:604\u201316.","journal-title":"Arthritis Rheumatol."},{"key":"777_CR19","doi-asserted-by":"publisher","first-page":"e001457","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7:e001457.","journal-title":"RMD Open."},{"key":"777_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: Results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74:475\u201385.","journal-title":"Arthritis Rheumatol."},{"key":"777_CR21","doi-asserted-by":"publisher","first-page":"e003977","DOI":"10.1136\/rmdopen-2023-003977","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Gossec L, Zimmerman M, et al. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo controlled study. RMD Open. 2024;10:e003977.","journal-title":"RMD Open."},{"key":"777_CR22","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s10067-024-06991-8","volume":"43","author":"CT Ritchlin","year":"2024","unstructured":"Ritchlin CT, Mease PJ, Boehncke WH, et al. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study. Clin Rheumatol. 2024;43:2551\u201363.","journal-title":"Clin Rheumatol."},{"key":"777_CR23","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-na\u00efve patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1126\u201336.","journal-title":"Lancet."},{"key":"777_CR24","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/ard.2009.122259","volume":"69","author":"M Schoels","year":"2010","unstructured":"Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis. 2010;69:1441\u20137.","journal-title":"Ann Rheum Dis."},{"key":"777_CR25","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C, et al. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66:936\u20139.","journal-title":"Ann Rheum Dis."},{"key":"777_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811\u20138.","journal-title":"Ann Rheum Dis."},{"key":"777_CR27","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","volume":"72","author":"PS Helliwell","year":"2013","unstructured":"Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986\u201391.","journal-title":"Ann Rheum Dis."},{"key":"777_CR28","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/acr.24046","volume":"72","author":"PS Helliwell","year":"2020","unstructured":"Helliwell PS, Deodhar A, Gottlieb AB, et al. Composite measures of disease activity in psoriatic arthritis: comparative instrument performance based on the efficacy of guselkumab in an interventional phase II trial. Arthritis Care Res (Hoboken). 2020;72:1579\u201388.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"777_CR29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3899\/jrheum.100857","volume":"38","author":"A Cauli","year":"2011","unstructured":"Cauli A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol. 2011;38:898\u2013903.","journal-title":"J Rheumatol."},{"key":"777_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353.","journal-title":"Ann Rheum Dis."},{"key":"777_CR31","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.3899\/jrheum.150595","volume":"42","author":"E Lubrano","year":"2015","unstructured":"Lubrano E, Perrotta FM, Parsons WJ, et al. Patient\u2019s global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity? J Rheumatol. 2015;42:2332\u20138.","journal-title":"J Rheumatol."},{"key":"777_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045\u201350.","journal-title":"Ann Rheum Dis."},{"key":"777_CR33","doi-asserted-by":"publisher","first-page":"e004062","DOI":"10.1136\/rmdopen-2023-004062","volume":"10","author":"SVJ Snoeck Henkemans","year":"2024","unstructured":"Snoeck Henkemans SVJ, de Jong PHP, Luime JJ, et al. Window of opportunity in psoriatic arthritis: the earlier the better? RMD Open. 2024;10:e004062.","journal-title":"RMD Open."},{"key":"777_CR34","doi-asserted-by":"publisher","first-page":"e002789","DOI":"10.1136\/rmdopen-2022-002789","volume":"9","author":"AB Gottlieb","year":"2023","unstructured":"Gottlieb AB, McInnes IB, Rahman P, et al. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis. RMD Open. 2023;9:e002789.","journal-title":"RMD Open."},{"key":"777_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jbspin.2015.06.018","volume":"83","author":"S Talli","year":"2016","unstructured":"Talli S, Etcheto A, Fautrel B, et al. Patient global assessment in psoriatic arthritis\u2014What does it mean? An analysis of 223 patients from the psoriatic arthritis impact of disease (PsAID) study. Joint Bone Spine. 2016;83:335\u201340.","journal-title":"Joint Bone Spine."},{"key":"777_CR36","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40744-020-00229-0","volume":"7","author":"E Lubrano","year":"2020","unstructured":"Lubrano E, Scriffignano S, Azuaga AB, et al. Impact of comorbidities on disease activity, patient global assessment, and function in psoriatic arthritis: a cross-sectional study. Rheumatol Ther. 2020;7:825\u201336.","journal-title":"Rheumatol Ther."},{"key":"777_CR37","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s40744-023-00592-8","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Gladman DD, Poddubnyy D, et al. Efficacy of guselkumab on axial-related symptoms through up to 2 years in adults with active psoriatic arthritis in the phase 3, randomized, placebo-controlled DISCOVER-2 study. Rheumatol Ther. 2023;10:1637\u201353.","journal-title":"Rheumatol Ther."},{"key":"777_CR38","doi-asserted-by":"publisher","first-page":"e715","DOI":"10.1016\/S2665-9913(21)00105-3","volume":"3","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Helliwell PS, Gladman DD, et al. Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. Lancet Rheumatol. 2021;3:e715\u201323.","journal-title":"Lancet Rheumatol."},{"key":"777_CR39","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1186\/s13063-022-06589-y","volume":"23","author":"DD Gladman","year":"2022","unstructured":"Gladman DD, Mease PJ, Bird P, et al. Efficacy and safety of guselkumab in biologic-naive patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial. Trials. 2022;23:743.","journal-title":"Trials."},{"issue":"Suppl 1","key":"777_CR40","first-page":"1173","volume":"79","author":"A Ogdie","year":"2020","unstructured":"Ogdie A, Husni ME, Scher J, et al. SAT0434 Minimal clinically important difference in outcome measures for use in clinical care and pragmatic trials in PsA. Ann Rheum Dis. 2020;79(Suppl 1):1173\u20134.","journal-title":"Ann Rheum Dis."},{"key":"777_CR41","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3899\/jrheum.140172","volume":"41","author":"PS Helliwell","year":"2014","unstructured":"Helliwell PS, FitzGerald O, Fransen J. Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. J Rheumatol. 2014;41:1212\u20137.","journal-title":"J Rheumatol."},{"key":"777_CR42","doi-asserted-by":"publisher","first-page":"4119","DOI":"10.1093\/rheumatology\/keac025","volume":"61","author":"MLM Mulder","year":"2022","unstructured":"Mulder MLM, Bertram AM, Wenink MH, et al. Defining the minimal important change (MIC) and meaningful change value (MCV) for the Psoriatic Arthritis Disease Activity Score (PASDAS) in a routine practice cohort of patients with psoriatic arthritis. Rheumatology (Oxford). 2022;61:4119\u201323.","journal-title":"Rheumatology (Oxford)."},{"issue":"Suppl 1","key":"777_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/annrheumdis-2021-eular.1622","volume":"80","author":"W Tillett","year":"2021","unstructured":"Tillett W, Day J, McHugh NJ, et al. OP0224 Continuous composite measures for routine care in psoriatic arthritis: thresholds of meaning and clinically important difference estimates for the 3 and 4 VAS scales from a UK multicentre study. Ann Rheum Dis. 2021;80 (Suppl 1):135.","journal-title":"Ann Rheum Dis."},{"key":"777_CR44","unstructured":"Institute for Quality and Efficiency in Health Care. General Methods Version 6.1. Jan 2022. https:\/\/www.iqwig.de\/methoden\/general-methods_version-6-1.pdf."}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00777-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-025-00777-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-025-00777-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T12:03:23Z","timestamp":1758369803000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-025-00777-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["777"],"URL":"https:\/\/doi.org\/10.1007\/s40744-025-00777-3","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"type":"print","value":"2198-6576"},{"type":"electronic","value":"2198-6584"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christopher T. Ritchlin: grant\/research support: AbbVie, Amgen, and UCB; consultant: AbbVie, Amgen, Eli Lilly, Gilead, Johnson & Johnson, Novartis, Pfizer, and UCB. Ennio Lubrano: honoraria: AbbVie, Amgen, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Novartis, and UCB. Ennio Lubrano is an Editorial Board member of Rheumatology and Therapy. Ennio Lubrano was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Maria Sole Chimenti: speaker honoraria\/research grants: Eli Lilly, AbbVie, UCB, Novartis, and Johnson & Johnson. Evan Leibowitz: employee: Johnson & Johnson; shareholder: Johnson & Johnson. Mohamed Sharaf: employee: Johnson & Johnson; shareholder: Johnson & Johnson. Emmanouil Rampakakis: employee: JSS Medical Research Inc.; consultant: Johnson & Johnson. Francois Nantel: consultant: Johnson & Johnson; shareholder: Johnson & Johnson. Frederic Lavie: employee: was an employee of Johnson & Johnson at the time this work was performed and currently an employee of Les Entreprises du M\u00e9dicament, Paris, France; shareholder: Johnson & Johnson. Atul Deodhar: consultant: Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB; research grants: Eli Lilly, Novartis, Pfizer, and UCB; speaker fees: Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The DISCOVER-2 (NCT03158285) study was conducted in accordance with the principles of the Declaration of Helsinki and International Council for Harmonization Guidelines for Good Clinical Practice. Each participating site\u2019s governing ethical body approved study protocols, and all participants provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}